Hos patienter, der får MabCampath som 1. linje- behandling, blev der opnået restitution af CD4+ tal til ≥200 celler/ µL på 6 måneder efter behandling, 2 måneder efter behandlingen var medianen dog 183 celler/ µl.
In patients receiving MabCampath as first line therapy, the recovery of CD4+ counts to ≥ 200 cells/ µl occurred by 6 months post-treatment, however, at 2 months post-treatment the median was 183 cells/μ l.